Is the FTSE 100 overvalued?
Just Eat continues strong expansion as revenue rises 47%
CEO Peter Plumb said of the results:
“The Just Eat team has once again delivered another period of strong growth. As I get to know the company, it is great to see the UK business in good health and positive momentum across our international markets, particularly in Canada where SkipTheDishes’ delivery expertise and relentless focus on customer service are driving excellent results. We will continue to invest for growth in technology, marketing and great people.“
Weir Group sinks as full year guidance is slashed
“In 2017 we continue to build on our leadership positions in rapidly improving main markets whilst investing to maximise the significant opportunities ahead of us. “As the North American onshore oil and gas industry continues to demonstrate its increased relevance as a source of global supply, our Oil & Gas business is fully leveraging its market leadership position in support of higher activity levels among customers. While international markets remained challenging the division has accelerated in 2017 as we expected and is well placed to continue to fully capture future opportunities. “In Minerals our brownfield solutions delivered good order growth with an increasing pipeline of future opportunities. Profits will be slightly lower than previously indicated due to project phasing, incremental investment in growth and one-off plant reconfiguration as we ensure the business is well set to benefit from increased momentum in 2018 and beyond.”
“At a group level, we anticipate strong growth in full year constant currency revenues and profits. Minerals profits are expected to be slightly lower than previously indicated while expectations for Oil & Gas and Flow Control are unchanged.”
BP shares rise following share buyback announcement
RBS swing into profit, financial position improves
Royal Bank of Scotland (LON:RBS) have continued their already positive year with a third successive quarter of profit. For the third quarter RBS made a profit of £392 million, pushing their profit for the year up to £1.33 billion.
Some quarters have suggested this leaves RBS in a strong position to finish the full-year in profit for the first time since their state funded bailout in 2008. RBS themselves have however expressed caution as they are yet to conclude a number of litigation cases in the US, as well as being under a fresh investigation by the Financial Conduct Authority over mistreatment of small business customers. The firm have already made provisions for these cases, whilst also warning that there may be the need for further substantial provisions. RBS has seen their net interest margin decline for both the third quarter and first nine months of the year, compared to the year previous. In the third quarter net interest margin fell five basis points to 2.12% and fell 2 basis points for the first nine months to 2.16% One off payments for PPI claims was £115 million for the quarter, leaving them with £979 million of provisions. This is an increase in payments from £81 million in Q2 2017, which was expected as new FCA media campaigns has had a significant impact on the number of claims. RBS’ long term target for Common Equity Tier 1 ratio is 13%, managing to be above this target for the quarter as it increased by 70 basis points to 15.5%. This strong performance reflected “continued RWA (Risk-Weighted Asset) reduction, the attributable profit and a reduction in the prudential valuation capital deduction, broadly offsetting the Capital Resolution losses taken in the quarter”. The group, that also owns Natwest, stated firm progress in all four of the target areas they have identified. Income has grown 7.5% for the year to date, operating expenses has been reduced by £708 million, capital usage has been reduced and they are moving toward resolving legacy issues.RBS shares have remained close to their opening price, increasing 0.4% to 282p at the time of writing, despite early strong performance.
Shire Pharmaceutical gains approval from European Commission
The biotechnology company Shire PLC (LON:SHP) has had a label extension approved by the European Commission. The label extension grants a new indication for FIRAZYR, allowing it to be used by adolescents and children aged two and older.
FIRAZYR is used to treat people with hereditary angioedema (HAE), which is a rare genetic diseases that specifically causes attacks of localised oedema. HAE is thought to affect one in 10,000-50,000 people worldwide.
Despite the label extension of FIRAZYR Shire have seen their share price drop 2% to 3517p. This is in anticipation of Shire delivering their third quarter results for 2017 tomorrow (October 27).
Analysts expect revenue for the rare disease specialist to rise 8% and earnings per share to increases by 15% on the previous year. Shire drugs Cinryze and Lialda may however perform worse than expected. Cinryze has suffered from a supply shortage and Lialda has been experiencing competition from Zydus.
